Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Zacks Research

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

A number of other equities analysts have also recently weighed in on the company. TD Cowen increased their price target on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Bank of America began coverage on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price target on the stock. Piper Sandler upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $40.00 to $65.00 in a report on Thursday, October 9th. Finally, Stifel Nicolaus lifted their target price on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Supernus Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $61.60.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $48.16 on Thursday. The firm has a 50 day simple moving average of $48.76 and a 200-day simple moving average of $46.10. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of -141.64, a price-to-earnings-growth ratio of 0.52 and a beta of 0.67. Supernus Pharmaceuticals has a 1-year low of $29.16 and a 1-year high of $57.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). The business had revenue of $170.00 million during the quarter, compared to analyst estimates of $175.82 million. Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The company’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.69 earnings per share. Equities analysts expect that Supernus Pharmaceuticals will post 2.38 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $50.41, for a total value of $1,008,200.00. Following the completion of the transaction, the senior vice president owned 15,496 shares of the company’s stock, valued at $781,153.36. This trade represents a 56.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Padmanabh P. Bhatt sold 710 shares of the business’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the transaction, the vice president owned 14,508 shares of the company’s stock, valued at approximately $644,735.52. This trade represents a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. 8.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Hantz Financial Services Inc. grew its position in shares of Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 281 shares in the last quarter. Torren Management LLC purchased a new position in Supernus Pharmaceuticals in the fourth quarter worth approximately $49,000. USA Financial Formulas acquired a new position in Supernus Pharmaceuticals during the 3rd quarter worth approximately $50,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $51,000. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 30.8% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 268 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.